Gallant

What Gallant does

Gallant is a San Diego-based animal health biotechnology company founded in 2018/2019, developing a single proprietary platform of allogeneic, off-the-shelf, ready-to-use uterine-derived mesenchymal stromal cell (UMSC) therapies for chronic inflammatory and immune-mediated diseases in companion animals. The company's core technology sources MSCs from healthy, FDA-qualified donor uterine tissue and manufactures them under cGMP, producing a standardized, donor-derived product stored and shipped at -80°C that can be administered via simple intravenous injection without sedation, anesthesia, surgical harvesting, or specialist referral — in direct contrast to traditional autologous stem cell therapy. Gallant's pipeline spans five indications: a lead candidate sonruvetcel (SNU-01) for refractory feline chronic gingivostomatitis (FCGS), plus programs in feline osteoarthritis, canine osteoarthritis, feline chronic kidney disease, and canine atopic dermatitis, all progressing through the FDA Center for Veterinary Medicine conditional approval pathway.

The company is pre-revenue and investigational-stage; all therapies are currently available only through FDA-authorized clinical trials funded by Gallant. Commercial product revenue is anticipated with FDA conditional approval of sonruvetcel in 2026, with canine OA targeted for 2028. Gallant's go-to-market model is a B2B channel delivering product to veterinary clinics through a flagship distribution partnership with MWI Animal Health — the first ultra-low temperature (-80°C) cold chain in veterinary medicine, with overnight nationwide shipping from Edwardsville, Kansas. The company has raised $33 million+ across a $15M+ Series A (January 2024, led by BOLD Capital) and an $18M Series B (July 2025, led by Digitalis Ventures with NovaQuest Capital Management), is supported by a RACE-approved continuing education platform (GallantU), and operates as a remote-friendly organization with headquarters in San Diego, California.

Name

Gallant

Legal name

Gallant

Website

https://gallant.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

Gallant is an animal health biotechnology company developing allogeneic, ready-to-use uterine-derived mesenchymal stem cell (UMSC) therapies for chronic inflammatory diseases in cats and dogs, with five products in its pipeline progressing through FDA conditional approval.

Ownership category

akta.pro rank

Product category

Veterinary Regenerative Medicine

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Veterinary Services (54194)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Medicated Feed Additives & Premixes (Veterinary Pharmaceuticals) (HLAMAEAN)

akta.pro secondary industry

Biologics & Immunotherapies (Non-vaccine) (HLAMAEAK)

Keywords

• Veterinary stem cell therapy
• Regenerative animal medicine
• Pet cell therapy
• Veterinary biotechnology
• Animal health therapeutics

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Pre-revenue / Investigational stage: Gallant is currently pre-revenue and pre-commercial. All therapies are investigational and not yet FDA-approved, available only through FDA-authorized clinical trials at qualified clinics. Commercial product revenue is anticipated with FDA conditional approval of sonruvetcel injectable suspension for cats with refractory Feline Chronic Gingivostomatitis, targeted in 2026.
2. Legacy revenue (pre-rebrand): Per a third-party Shark Tank article, Gallant experienced revenues reaching $5 million in 2023 prior to its current focus on FDA-regulated allogeneic stem cell therapy. (Note: this reference predates the current regenerative medicine business model and may refer to the predecessor direct-to-consumer pet care business under founder Aaron Hirschhorn who passed away in 2021.)

Pricing tiers

Go-to-market motion4 records

Distribution channels3 records

Marketing channels8 records

Core offering

Gallant is developing allogeneic, off-the-shelf, ready-to-use uterine-derived mesenchymal stromal cell (UMSC) therapies for cats and dogs, manufactured under cGMP and administered via simple intravenous injection. Its lead candidate, sonruvetcel injectable suspension, targets refractory Feline Chronic Gingivostomatitis (FCGS), with additional pipeline programs for feline and canine osteoarthritis, feline chronic kidney disease, and canine atopic dermatitis. All therapies are investigational and available only through FDA-authorized clinical trials until FDA conditional approval is granted.

Product overview

Gallant is an animal health biotechnology company offering a single unified platform of ready-to-use, donor-derived umbilical cord mesenchymal stem cell (UMSC) therapies for pets, organized as a lead product (sonruvetcel/SNU-01 for feline FCGS) plus a pipeline of additional indications including canine osteoarthritis, feline osteoarthritis, feline chronic kidney disease, and canine atopic dermatitis. All therapeutic products share the same underlying ready-to-use UMSC manufacturing platform, produced under cGMP, and each indication is being progressed through the FDA Center for Veterinary Medicine conditional approval pathway. GallantU is an add-on RACE-approved continuing education service that supports veterinary professionals in administering and adopting the stem cell therapies in the core pipeline.

Differentiator

Problem solved

Functional benefit

Brands

• GallantU: Free, RACE-approved continuing education (CE) platform for veterinary professionals, offering live and on-demand courses on regenerative medicine, including stem cell biology, clinical application, and emerging evidence. Hosted at learn.gallant.com.

Products and services

• sonruvetcel (SNU-01) Injectable Suspension Ready-to-use allogeneic uterine-derived mesenchymal stem cell (UMSC) injectable suspension in development for refractory Feline Chronic Gingivostomatitis (FCGS); FDA Technical Section Complete and pursuing CVM conditional approval. Designed as a simple IV-administered, off-the-shelf therapy for veterinary clinics.
• Canine Osteoarthritis Stem Cell Therapy Ready-to-use IV-administered UMSC therapy in development for canine osteoarthritis; pilot data (88-dog randomized placebo-controlled study) showed statistically significant improvement at Day 60 and 90, and the program is eligible for FDA-CVM expanded conditional approval pathway with conditional approval targeted for 2028.
• Feline Osteoarthritis Stem Cell Therapy Ready-to-use IV-administered UMSC therapy in development for feline osteoarthritis; randomized, masked, placebo-controlled pilot of 35 client-owned cats showed 76.2% improvement (CSOM) vs 36.4% placebo at Day 90, and 81% improvement per owner and vet assessments. Eligible for FDA-CVM expanded conditional approval pathway.
• Feline Chronic Kidney Disease Stem Cell Therapy
• Canine Atopic Dermatitis Stem Cell Therapy
• GallantU Continuing Education Platform

Quantifiable outcome

• 76% of rFCGS-treated cats showed improved quality of life (n=46)
• +8 more outcomes

Segments5 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered core and flagship.

• American Animal Hospital Association (AAHA)coreGTM or Marketing Partner · 2 March 2026AAHA-Gallant collaboration on the national survey "Regenerative Medicine in Veterinary Practice: Perceptions, Experience, and Outlook" which gathered responses from more than 1,000 U.S. small animal veterinary professionals. AAHA is also listed as a Mission Partner on the Gallant website.
• MWI Animal HealthflagshipChannel Partner/ Reseller/ Distributor · 27 February 2026MWI Animal Health partnership to create the first ultra-low temperature cold chain in veterinary medicine, designed to support delivery of Gallant's anticipated first FDA-approved off-the-shelf stem cell therapy for cats with refractory feline chronic gingivostomatitis. Under the agreement, MWI will develop scalable ultra-low temperature fulfillment infrastructure enabling -80°C storage and overnight shipping nationwide (including Alaska, Hawaii, and Puerto Rico) from its Edwardsville, Kansas distribution center. The partnership aims to establish infrastructure for Gallant's broader pipeline of disease-modifying stem cell therapies.
• Ethos DiscoverycoreStrategic or Co-development Partner · 3 October 2023Collaboration between Ethos Discovery (a non-profit incubator of scientific innovation) and Gallant on a study evaluating allogeneic MSC therapy in 13 Pugs with presumptive early necrotizing meningoencephalitis (NME). The study was led by veterinary neurologist Dr. Rebecca Windsor and conducted by Ethos Discovery in collaboration with the regenerative medicine laboratory at UC Davis and Gallant. Published in Journal of the American Veterinary Medical Association.

Scale indicators18 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• VetStem Biopharma: VetStem is the most established veterinary stem cell therapy company in the U.S., offering autologous adipose-derived stem cell services for dogs, cats, and horses. It is the closest direct competitor to Gallant — both target the same veterinary regenerative medicine opportunity, but VetStem uses autologous (patient-derived) cells requiring surgical harvest and processing, whereas Gallant's allogeneic, off-the-shelf IV format is structurally differentiated. Notably, Gallant's CTO Carolyn Wrightson and Director of Finance April Treadwell previously held leadership roles at VetStem.
• MediVet (Animal Health Partners): MediVet provides animal stem cell technologies and laboratory services for veterinarians, including adipose-derived stem cell kits. It competes in the same veterinary regenerative medicine space as Gallant and VetStem, offering clinics autologous processing infrastructure and consumables.
• Ardent Animal Health: Ardent Animal Health is a veterinary regenerative medicine company offering stem cell therapy services for companion animals, overlapping with Gallant's customer segment and product category before its acquisition/integration with VetStem.

Emerging players

• Animal Cell Therapies: Animal Cell Therapies focuses on regenerative medicine solutions for companion animals, including stem cell and platelet-rich plasma therapies. It is a smaller emerging player in the same veterinary regenerative medicine category as Gallant, with overlapping customer base of veterinary clinics.

Broad incumbents

• Zoetis: Zoetis is the largest global animal health pharmaceutical company, offering therapeutics, diagnostics, and vaccines across companion animals and livestock. As a broad incumbent with deep veterinary distribution relationships and significant R&D capacity, Zoetis is both a potential competitor (could enter stem cell therapy) and a potential strategic acquirer of companies like Gallant. Board member Darryl Rawlings (Trupanion CEO) and ex-Pfizer Animal Health executives on Gallant's network reflect this adjacency.
• Elanco Animal Health: Elanco is a major global animal health company offering therapeutics and diagnostics for companion animals and livestock. Gallant board member Aaron Schacht is CEO of BiomEdit and previously led R&D and regulatory affairs at Elanco, illustrating the executive overlap between Gallant's leadership and major incumbents.
• IDEXX Laboratories: IDEXX is the leading veterinary diagnostics company and a major player in companion animal health. While not a direct stem cell therapy competitor, IDEXX sits in the same veterinarian customer ecosystem and could expand into therapeutics or partner with a regenerative medicine player like Gallant. Gallant SVP Jennifer Klein previously held leadership roles at IDEXX.
• Ceva Animal Health: Ceva is a global animal health pharmaceutical company with a significant companion animal therapeutics portfolio. Dr. Valentine Williams (Gallant's SVP of Clinical Development) previously worked at Ceva, signaling deep familiarity between Gallant's leadership and this incumbent. Ceva could be a potential strategic partner or acquirer of regenerative medicine assets.
• Dechra Pharmaceuticals: Dechra is a UK-listed global specialist in veterinary pharmaceuticals, with a strong companion animal therapeutics portfolio. As a broad incumbent with endocrinology, dermatology, and other therapeutic franchises, Dechra is a comparable strategic acquirer of novel veterinary therapeutics platforms including regenerative medicine.

Others

• Trupanion: Trupanion is a leading pet medical insurance provider in North America, covering more than 500,000 pets. It is not a direct therapy competitor but is a critical ecosystem participant whose reimbursement decisions will materially shape demand for premium-priced therapies like Gallant's stem cell products. Gallant board member Darryl Rawlings is Trupanion's founder and CEO.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks4 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/gallant
• Xx.com/gallantpet

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles19 records

Funding overview

Funding rounds9 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gallant